Enzon Pharmaceuticals (ENZN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ENZN Stock Summary
- Enzon Pharmaceuticals Inc's market capitalization of $22,264,381 is ahead of only 3.61% of US-listed equities.
- For ENZN, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
- Revenue growth over the past 12 months for Enzon Pharmaceuticals Inc comes in at 1,248.08%, a number that bests 99.17% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ENZN, based on their financial statements, market capitalization, and price volatility, are LMPX, MSB, NVFY, HLG, and PFBX.
- Visit ENZN's SEC page to see the company's official filings. To visit the company's web site, go to www.enzon.com.
ENZN Valuation Summary
- In comparison to the median Healthcare stock, ENZN's price/earnings ratio is 129.04% lower, now standing at -10.6.
- ENZN's price/earnings ratio has moved down 369.8 over the prior 243 months.
- ENZN's price/sales ratio has moved down 64.3 over the prior 243 months.
Below are key valuation metrics over time for ENZN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ENZN | 2021-08-31 | 34.3 | 3.9 | -10.6 | 28.4 |
| ENZN | 2021-08-30 | 35.3 | 4.0 | -10.9 | 27.6 |
| ENZN | 2021-08-27 | 40.5 | 4.6 | -12.5 | 23.1 |
| ENZN | 2021-08-26 | 41.6 | 4.7 | -12.8 | 22.2 |
| ENZN | 2021-08-25 | 38.8 | 4.4 | -12.0 | 24.6 |
| ENZN | 2021-08-24 | 39.5 | 4.4 | -12.2 | 24.0 |
ENZN Growth Metrics
- The year over year net cashflow from operations growth rate now stands at -100.48%.
- Its 5 year cash and equivalents growth rate is now at -47.16%.
- Its 4 year net cashflow from operations growth rate is now at -14.66%.
The table below shows ENZN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 0.701 | -0.501 | -2.492 |
| 2021-09-30 | 0.706 | -0.796 | -2.638 |
| 2021-06-30 | 0.714 | -0.794 | -2.313 |
| 2021-03-31 | 0.431 | -0.033 | -2.024 |
| 2020-12-31 | 0.052 | -0.38 | -1.771 |
| 2020-09-30 | 0.067 | 0.901 | -1.147 |
ENZN Stock Price Chart Interactive Chart >
ENZN Price/Volume Stats
| Current price | $0.29 | 52-week high | $0.76 |
| Prev. close | $0.30 | 52-week low | $0.25 |
| Day low | $0.29 | Volume | 2,500 |
| Day high | $0.29 | Avg. volume | 36,200 |
| 50-day MA | $0.31 | Dividend yield | N/A |
| 200-day MA | $0.35 | Market Cap | 21.52M |
Enzon Pharmaceuticals (ENZN) Company Bio
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Latest ENZN News From Around the Web
Below are the latest news stories about Enzon Pharmaceuticals Inc that investors may wish to consider to help them evaluate ENZN as an investment opportunity.
Enzon Pharmaceuticals (OTCMKTS:ENZN) & Icosavax (NASDAQ:ICVX) Head-To-Head ContrastEnzon Pharmaceuticals (OTCMKTS:ENZN) and Icosavax (NASDAQ:ICVX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Analyst Recommendations This is a summary of current ratings and price targets for Enzon Pharmaceuticals and [] The post Enzon Pharmaceuticals (OTCMKTS:ENZN) & Icosavax (NASDAQ:ICVX) Head-To-Head Contrast appeared first on ETF Daily News . |
Enzon Pharmaceuticals (OTCMKTS:ENZN) and Icosavax (NASDAQ:ICVX) Head to Head ReviewIcosavax (NASDAQ:ICVX) and Enzon Pharmaceuticals (OTCMKTS:ENZN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Analyst Recommendations This is a breakdown of current recommendations for Icosavax and Enzon Pharmaceuticals, as reported [] |
Contrasting Enzon Pharmaceuticals (ENZN) and Its PeersEnzon Pharmaceuticals (OTCMKTS: ENZN) is one of 232 public companies in the Biological products, except diagnostic industry, but how does it contrast to its competitors? We will compare Enzon Pharmaceuticals to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations. Analyst Recommendations This is a summary [] |
Enzon Pharmaceuticals (ENZN) and Its Rivals Financial ContrastEnzon Pharmaceuticals (OTCMKTS: ENZN) is one of 232 publicly-traded companies in the Biological products, except diagnostic industry, but how does it compare to its peers? We will compare Enzon Pharmaceuticals to related companies based on the strength of its profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends. Valuation and Earnings This table compares [] |
Critical Contrast: Enzon Pharmaceuticals (ENZN) vs. The CompetitionEnzon Pharmaceuticals (OTCMKTS: ENZN) is one of 232 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Enzon Pharmaceuticals to related companies based on the strength of its risk, earnings, profitability, analyst recommendations, institutional ownership, dividends and valuation. Risk & Volatility Enzon Pharmaceuticals has […] |
ENZN Price Returns
| 1-mo | -7.99% |
| 3-mo | -9.38% |
| 6-mo | -21.52% |
| 1-year | -49.97% |
| 3-year | 467.51% |
| 5-year | 465.30% |
| YTD | -15.33% |
| 2021 | 37.88% |
| 2020 | 20.58% |
| 2019 | 284.33% |
| 2018 | -6.78% |
| 2017 | -26.00% |
Continue Researching ENZN
Here are a few links from around the web to help you further your research on Enzon Pharmaceuticals Inc's stock as an investment opportunity:Enzon Pharmaceuticals Inc (ENZN) Stock Price | Nasdaq
Enzon Pharmaceuticals Inc (ENZN) Stock Quote, History and News - Yahoo Finance
Enzon Pharmaceuticals Inc (ENZN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...